Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,184.69
+5.76 (+0.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
33
34
Next >
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
February 11, 2022
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.
Via
Investor's Business Daily
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
February 10, 2022
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)
Via
Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
The
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Analyst Ratings For Regeneron Pharmaceuticals
January 31, 2022
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:
Via
Benzinga
Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
January 28, 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
February 08, 2022
Keybanc raised Take-Two Interactive Software, Inc. (NASDAQ: TTWO) price target from $185 to $190. Take-Two Interactive shares fell 2.8% to $170.21 in pre-market trading.
Via
Benzinga
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
February 07, 2022
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.
Via
Investor's Business Daily
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
February 05, 2022
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed.
Via
Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
February 04, 2022
The major indexes slashed weekly gains after Monday's follow-through day.
Via
Investor's Business Daily
Regeneron Scores Quarterly Beat On Covid Cocktail — But Future Sales Are Shaky
February 04, 2022
Regeneron posted 104% sales growth, including $2.3 billion from REGEN-COV.
Via
Investor's Business Daily
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales
February 04, 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned
Via
Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: Regeneron Pharmaceuticals Q4 Earnings
February 04, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 4, 2022
February 04, 2022
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter.
Via
Benzinga
Earnings Preview For Regeneron Pharmaceuticals
February 03, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.
Via
Benzinga
3 Biotech Stocks That Could Boom or Bust in Q1
February 01, 2022
The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future.
Via
InvestorPlace
5 Things To Expect This Week
January 31, 2022
While the "January effect" was rather disappointing, February kicks off with an important week ahead for many types of investors.
Via
InvestorPlace
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Via
Benzinga
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
January 31, 2022
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a posi
Via
Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
January 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting
January 25, 2022
Pre-open movers U.S. stock futures traded mostly lower in early pre-market trade. The Dow Jones settled higher by around 100 points on Monday after tumbling more than 1,000 points...
Via
Benzinga
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
January 24, 2022
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their...
Via
Benzinga
Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
January 24, 2022
The demand for monoclonal antibody treatments to help in the recovery of COVID-19 patients has outpaced the supply, and this situation runs the risk of becoming more acute as...
Via
Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in...
Via
Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
January 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...
Via
Benzinga
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
January 19, 2022
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
Via
Benzinga
WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge
January 14, 2022
An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc...
Via
Benzinga
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
January 13, 2022
Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma...
Via
Benzinga
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.